Rifaximine in the treatment of hepatic encephalopathy;Rifaximin v léčbě jaterní encefalopatie

Vnitrni Lekarstvi

Volumn 48, Issue 6, 2002, Pages 578-582

  Lata, Jan ^a   Hulek P ^a   Fejfar, T ^a   Spicak J ^a   Drastich, P ^a   Marecek Z ^a   Bruha R ^a   Husova L ^a   Senkyrik M ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Liver cirrhosis; Liver encephalopathy; Non absorbable antibiotics; Rifaximine

Indexed keywords

ANTIBIOTIC AGENT; RIFAMYCIN DERIVATIVE; RIFAXIMIN; ANTIINFECTIVE AGENT; RIFAMYCIN;

AMMONIA BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; FEMALE; MALE; MIDDLE AGED;

ANTI-INFECTIVE AGENTS; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIFAMYCINS;

EID: 0036282351     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. TIPS and hepatic encephalopathy
2. Hepatic encephalopathy: Disorder of multiple neurotransmitter systems
3. Glutamate transporters in hepatic encephalopathy
4. Ammonia and GABAergic neurotransmission: Interrelated factors in the pathogenesis of hepatic encephalopathy
5. Enhanced renal ammonia production is major cause of hyperammonemia after a simulated upper gastrointestinal bleed in patients with cirrhosis of the liver
6. ESPEN guidelines for nutrition in liver disease and transplantation
7. Energy and protein requirements of patients with chronic liver disease
8. Vegetable versus animal protein in diet in cirrhotic patients with chronic encephalopathy: A randomized cross-over comparison
9. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: A controled, double-blind clinical trial
10. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomized trial
11. Treatment of acute hepatic encephalopathy (HE) with rifaximin in comparison with lactitol. A multicentre, double-blind, double-dummy, randomized controlled trial
12. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: A double blind, randomized, dose-finding multi-centre study